Episode Details

In their Q4 2025 earnings report, Moderna announced a financial beat with $678 million in revenue and a reduced net loss compared to the previous year. The company successfully executed a $2.2 billion cost-reduction plan while finishing 2025 with $8.1 billion in cash. Despite this financial stability, the FDA issued a refusal-to-file for their seasonal flu vaccine, prompting a Type A meeting to resolve regulatory hurdles in the United States. Looking forward to 2026, management anticipates up to 10% revenue growth fueled by international partnerships in the U.K., Canada, and Australia. Additionally, the company reported positive five-year data for its individualized cancer therapy and expects multiple clinical trial readouts across its oncology and rare disease pipelines.